Skip to content
6-K

Foreign Interim / Material

PHAXIAM Therapeutics S.A.

0001624422-23-000044

← back to feed
Filed
Sep 26, 2023 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q2 2023 · Jun 30, 2023 3.28M sh
Shares Diluted restated Q2 2023 · Jun 30, 2022 3.1M sh
Operating Cash Flow Q2 2023 · Jun 30, 2023 −€11.9M
Operating Cash Flow Q2 2023 · Jun 30, 2022 −€20.69M
Cash And Equivalents Q2 2023 · Jun 30, 2023 €25.19M
Cash And Equivalents Q2 2023 · Dec 31, 2022 €38.79M
Stockholders Equity Q2 2023 · Jun 30, 2023 €36.63M
Stockholders Equity Q2 2023 · Dec 31, 2022 €23.49M
Stockholders Equity Q2 2023 · Jun 30, 2022 €22.44M
Stockholders Equity Q2 2023 · Dec 31, 2021 €22.85M
Current Liabilities Q2 2023 · Jun 30, 2023 €17.39M
Current Liabilities Q2 2023 · Dec 31, 2022 €11.68M
Current Assets Q2 2023 · Jun 30, 2023 €30.92M
Current Assets Q2 2023 · Dec 31, 2022 €42.63M
Total Assets Q2 2023 · Jun 30, 2023 €65.53M
Total Assets Q2 2023 · Dec 31, 2022 €45.81M
Eps Diluted Q2 2023 · Jun 30, 2023 −€3.71
Eps Diluted restated Q2 2023 · Jun 30, 2022 −€0.33
Eps Basic Q2 2023 · Jun 30, 2023 −€3.71
Eps Basic restated Q2 2023 · Jun 30, 2022 −€0.33
Rd Expense Q2 2023 · Jun 30, 2023 €3.43M
Rd Expense Q2 2023 · Jun 30, 2022 €17.3M
Net Income Q2 2023 · Jun 30, 2023 −€12.2M
Net Income Q2 2023 · Jun 30, 2022 −€1.02M
Operating Income Q2 2023 · Jun 30, 2023 −€12.4M
Operating Income Q2 2023 · Jun 30, 2022 €93K
Revenue Q2 2023 · Jun 30, 2023 €0
Revenue Q2 2023 · Jun 30, 2022 €0